This is a pure binary catalyst event. The stock will gap sharply on the topline data release in August 2026 — either a positive readout (trial success) or a negative one (trial failure). Traders should position for the data release and consider the asymmetric payoff: a positive result could unlock a large unserved PH-HFpEF market, while a negative result would likely devastate the stock. Monitor for any abstract teaser or data leaks ahead of the ESC presentation on August 29.
Price Chart
Executive Summary
Tenax Therapeutics announced that results from its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) in PH-HFpEF will be presented at a Late-Breaking Clinical Science session at ESC Congress 2026 (Aug 28-31, Munich). The company now expects to report topline data in August 2026, with database lock and statistical analysis proceeding in the weeks ahead. This is a binary catalyst event for a development-stage company with no approved products and a $353M market cap — the stock will move sharply on the data readout.
Key Facts
- Phase 3 LEVEL trial results to be presented in Late-Breaking Clinical Science session at ESC Congress 2026 (Aug 28-31, Munich)
- Topline data expected in August 2026; database lock and statistical analysis proceeding in weeks ahead
- Trial enrolled over 230 patients with PH-HFpEF; powered at >90% to detect a 25-meter change in 6MWD (primary endpoint) per December 2025 BSSR
- TNX-103 (oral levosimendan) is a registrational Phase 3 candidate; no approved product exists for PH-HFpEF
- Company owns global rights to develop and commercialize levosimendan
Financial Impact
Binary catalyst — stock will reprice on topline data in August 2026. No financial figures reported in filing.
Risk Factors
- Phase 3 trial failure — primary endpoint (6MWD) may not be met despite >90% powering
- Binary binary event risk: stock will gap sharply in either direction on topline data in August 2026
- No approved product or revenue; company is pre-commercial with no financial data in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-293485 |
| Document: d20457dex991.htm | 0001193125-26-293485 |
| Document: 0001193125-26-293485-index-headers.html | 0001193125-26-293485 |
| Document: 0001193125-26-293485-index.html | 0001193125-26-293485 |
| Document: 0001193125-26-293485.txt | 0001193125-26-293485 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.76 (+29.41%) |
Oct 13, 2026 14d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.76 (+10.00%) |
Oct 9, 2026 17d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.76 (−3.83%) |
Oct 8, 2026 18d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.76 (−5.88%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.76 (−7.37%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.76 (−17.37%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.76 (−4.35%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.76 (+28.00%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.76 (+28.00%) |
Jul 31, 2026 12w ago | 8-K | $13.70 $13.44 | ▼ −1.90% | ▼ −5.41% | $1.76 (−87.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers